Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.
<h4>Background</h4>Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard of care (SOC) for venous thromboembolism (VTE) treatment and prevention. Although novel oral anti-coagulants (NOACs) have been compared with SOC in this indication, no h...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144856&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850100127042109440 |
|---|---|
| author | A T Cohen M Hamilton S A Mitchell H Phatak X Liu A Bird D Tushabe S Batson |
| author_facet | A T Cohen M Hamilton S A Mitchell H Phatak X Liu A Bird D Tushabe S Batson |
| author_sort | A T Cohen |
| collection | DOAJ |
| description | <h4>Background</h4>Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard of care (SOC) for venous thromboembolism (VTE) treatment and prevention. Although novel oral anti-coagulants (NOACs) have been compared with SOC in this indication, no head-to-head randomised controlled trials (RCTs) have directly compared NOACs. A systematic review and network meta-analysis (NMA) were conducted to compare the efficacy and safety of NOACs for the initial and long-term treatment of VTE.<h4>Methods</h4>Electronic databases (accessed July 2014) were systematically searched to identify RCTs evaluating apixaban, dabigatran, edoxaban, and rivaroxaban versus SOC. Eligible patients included adults with an objectively confirmed deep vein thrombosis (DVT), pulmonary embolism (PE) or both. A fixed-effect Bayesian NMA was conducted for outcomes of interest, and results were presented as relative risks (RR) and 95% credible intervals (Crl).<h4>Results</h4>Six Phase III RCTs met criteria for inclusion: apixaban (one RCT; n = 5,395); rivaroxaban (two RCTs; n = 3,423/4,832); dabigatran (two RCTs; n = 2,539/2,568); edoxaban (one RCT; n = 8,240). There were no statistically significant differences between the NOACs with regard to the risk of 'VTE and VTE-related death. Apixaban treatment was associated with the most favourable safety profile of the NOACs, showing a statistically significantly reduced risk of 'major or clinically relevant non-major (CRNM) bleed' compared with rivaroxaban (0.47 [0.36, 0.61]), dabigatran (0.69 [0.51, 0.94]), and edoxaban (0.54 [0.41, 0.69]). Dabigatran was also associated with a significantly lower risk of 'major or CRNM bleed' compared with rivaroxaban (0.68 [0.53, 0.87]) and edoxaban (0.77 [0.60, 0.99]).<h4>Conclusions</h4>Indirect comparisons showed statistically similar reductions in the risk of 'VTE or VTE-related death for all NOACs. In contrast, reductions in 'major or CRNM bleed' for initial/long-term treatment were significantly better with apixaban compared with all other NOACs, and with dabigatran compared with rivaroxaban and edoxaban. Results from the current analysis indicate that the NOACs offer clinical benefit over conventional therapy while highlighting relative differences in their bleeding profile. |
| format | Article |
| id | doaj-art-b8b44e73dab04dd391fc3f63f42434b5 |
| institution | DOAJ |
| issn | 1932-6203 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-b8b44e73dab04dd391fc3f63f42434b52025-08-20T02:40:21ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-011012e014485610.1371/journal.pone.0144856Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.A T CohenM HamiltonS A MitchellH PhatakX LiuA BirdD TushabeS Batson<h4>Background</h4>Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard of care (SOC) for venous thromboembolism (VTE) treatment and prevention. Although novel oral anti-coagulants (NOACs) have been compared with SOC in this indication, no head-to-head randomised controlled trials (RCTs) have directly compared NOACs. A systematic review and network meta-analysis (NMA) were conducted to compare the efficacy and safety of NOACs for the initial and long-term treatment of VTE.<h4>Methods</h4>Electronic databases (accessed July 2014) were systematically searched to identify RCTs evaluating apixaban, dabigatran, edoxaban, and rivaroxaban versus SOC. Eligible patients included adults with an objectively confirmed deep vein thrombosis (DVT), pulmonary embolism (PE) or both. A fixed-effect Bayesian NMA was conducted for outcomes of interest, and results were presented as relative risks (RR) and 95% credible intervals (Crl).<h4>Results</h4>Six Phase III RCTs met criteria for inclusion: apixaban (one RCT; n = 5,395); rivaroxaban (two RCTs; n = 3,423/4,832); dabigatran (two RCTs; n = 2,539/2,568); edoxaban (one RCT; n = 8,240). There were no statistically significant differences between the NOACs with regard to the risk of 'VTE and VTE-related death. Apixaban treatment was associated with the most favourable safety profile of the NOACs, showing a statistically significantly reduced risk of 'major or clinically relevant non-major (CRNM) bleed' compared with rivaroxaban (0.47 [0.36, 0.61]), dabigatran (0.69 [0.51, 0.94]), and edoxaban (0.54 [0.41, 0.69]). Dabigatran was also associated with a significantly lower risk of 'major or CRNM bleed' compared with rivaroxaban (0.68 [0.53, 0.87]) and edoxaban (0.77 [0.60, 0.99]).<h4>Conclusions</h4>Indirect comparisons showed statistically similar reductions in the risk of 'VTE or VTE-related death for all NOACs. In contrast, reductions in 'major or CRNM bleed' for initial/long-term treatment were significantly better with apixaban compared with all other NOACs, and with dabigatran compared with rivaroxaban and edoxaban. Results from the current analysis indicate that the NOACs offer clinical benefit over conventional therapy while highlighting relative differences in their bleeding profile.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144856&type=printable |
| spellingShingle | A T Cohen M Hamilton S A Mitchell H Phatak X Liu A Bird D Tushabe S Batson Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. PLoS ONE |
| title | Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. |
| title_full | Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. |
| title_fullStr | Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. |
| title_full_unstemmed | Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. |
| title_short | Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis. |
| title_sort | comparison of the novel oral anticoagulants apixaban dabigatran edoxaban and rivaroxaban in the initial and long term treatment and prevention of venous thromboembolism systematic review and network meta analysis |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0144856&type=printable |
| work_keys_str_mv | AT atcohen comparisonofthenoveloralanticoagulantsapixabandabigatranedoxabanandrivaroxabanintheinitialandlongtermtreatmentandpreventionofvenousthromboembolismsystematicreviewandnetworkmetaanalysis AT mhamilton comparisonofthenoveloralanticoagulantsapixabandabigatranedoxabanandrivaroxabanintheinitialandlongtermtreatmentandpreventionofvenousthromboembolismsystematicreviewandnetworkmetaanalysis AT samitchell comparisonofthenoveloralanticoagulantsapixabandabigatranedoxabanandrivaroxabanintheinitialandlongtermtreatmentandpreventionofvenousthromboembolismsystematicreviewandnetworkmetaanalysis AT hphatak comparisonofthenoveloralanticoagulantsapixabandabigatranedoxabanandrivaroxabanintheinitialandlongtermtreatmentandpreventionofvenousthromboembolismsystematicreviewandnetworkmetaanalysis AT xliu comparisonofthenoveloralanticoagulantsapixabandabigatranedoxabanandrivaroxabanintheinitialandlongtermtreatmentandpreventionofvenousthromboembolismsystematicreviewandnetworkmetaanalysis AT abird comparisonofthenoveloralanticoagulantsapixabandabigatranedoxabanandrivaroxabanintheinitialandlongtermtreatmentandpreventionofvenousthromboembolismsystematicreviewandnetworkmetaanalysis AT dtushabe comparisonofthenoveloralanticoagulantsapixabandabigatranedoxabanandrivaroxabanintheinitialandlongtermtreatmentandpreventionofvenousthromboembolismsystematicreviewandnetworkmetaanalysis AT sbatson comparisonofthenoveloralanticoagulantsapixabandabigatranedoxabanandrivaroxabanintheinitialandlongtermtreatmentandpreventionofvenousthromboembolismsystematicreviewandnetworkmetaanalysis |